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Abstract We have identified in rat vascular smooth muscle cells
(SMCs) the simultaneous expression of two TGF-L type I
receptor (ALK-5) cDNAs, occurring as a consequence of
alternate usage of AG splice acceptor motifs separated by 12
nucleotides located at an intron-exon junction. When translated
the resultant full length proteins differ from each other only by
the in-frame presence or absence of Gly-Pro-Phe-Ser residues
adjacent to their transmembrane domain. Stable expression of
these alternate ALK-5 isoforms in ALK-5-deficient cells demon-
strated that both were competent in signaling TGF-L-induced
growth inhibition and gene transcription, but with an apparently
distinct potency. Our data suggest that alternate splicing within
the ALK-5 gene is an important mechanism whereby SMCs may
regulate their response to TGF-L.
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1. Introduction
Transforming growth factor-L (TGF-L) is a multifunctional
cytokine/growth factor which has been implicated in a variety
of vascular pathologies, including vessel remodeling after an-
gioplasty [1], the development of atherosclerotic lesions [2],
and the development of vascular hypertrophy in hypertensives
[3]. Three closely related TGF-L isoforms, -L1, -L2, and -L3,
are present in vascular smooth muscle cells (SMCs) [4] and are
capable of either inhibiting or stimulating the proliferation of
these cells [5], such e¡ects elicited through interaction with cell
surface receptors that possess serine/threonine kinase activity
[6]. Initially, TGF-L binds to the type II receptor (TLR-II), a
constitutively autophosphorylated kinase, and then this li-
gand-receptor complex recruits and transphosphorylates an
appropriate type I receptor (mostly TLR-I/ALK-5), thereby
initiating intracellular signaling [6,7].
The TLR-II:TGF-L :ALK-5 complex formed has been pro-
posed to exist as a heterotetramer in which two molecules of
TLR-II and ALK-5 are each present [8], and their association
involves interactions between both extracellular and intracel-
lular domains of each receptor [9]. The mechanisms by which
such complexes initiate diverse TGF-L signaling patterns are
still unclear, but may involve interactions between di¡erent
functional receptor variants possibly arising as a consequence
of alternate splicing events. Evidence that such processes oc-
curring within the ALK-5 gene could generate multiple iso-
forms of this receptor has been provided by our recent de-
scription [10] of the expression of an ALK-5 cDNA in rat
SMCs distinct from the initially isolated ALK-5 cDNA [11]
in that it harbored an in-frame 12 nucleotide deletion in the
extracellular region encoding the Gly-Pro-Phe-Ser motif adja-
cent to the transmembrane domain, a region rich in proline
residues in both the rat and human ALK-5 proteins [11,12].
Deletion or insertion of proline residues/motifs in proteins via
naturally occurring nucleotide substitution or aberrant splic-
ing events is known to markedly a¡ect conformational con-
straints, and therefore biological activity, of such proteins
[13]. Thus, a mutation within the extracellular region of the
growth hormone receptor causing a change from glutamine to
proline not only alters the normal conformation of the recep-
tor, but also prevents growth hormone binding [14]. Proline
residues that introduce kinks into transmembrane helices of G
protein-coupled receptors are also critical determinants of li-
gand binding, and receptor signal transduction [15].
Thus, because of the importance of proline residues in reg-
ulating receptor structure and signal transduction, our aims in
the current study were to: (i) elucidate whether SMCs were
capable of expressing both ‘long’ and ‘short’ ALK-5 isoforms,
di¡ering from each other by the presence or absence of the 12
nucleotides encoding the amino acids Gly-Pro-Phe-Ser, (ii)
con¢rm whether these isoforms arise as a consequence of al-
ternate splicing events within the ALK-5 gene, (iii) determine
the functional signi¢cance of this alternate ALK-5 isoform
expression. Our data indicate that SMCs simultaneously ex-
press both the long and short ALK-5 isoforms via alternate
usage of AG splice acceptor motifs separated by 12 nucleo-
tides located at an intron-exon junction. Both ALK-5 iso-
forms are processed in a similar manner intracellularly, and
are competent in transducing growth inhibition and gene tran-
scription in response to TGF-L1. However, a non-redundant
physiological role for these isoforms appears to exist given
that their capacity to elicit such responses is not strictly equi-
potent, suggesting that their tissue-speci¢c expression levels
may provide an important mechanism whereby the cellular
response to TGF-L is regulated.
2. Materials and methods
2.1. Cell culture, DNA extraction and polymerase chain reaction
(PCR), and RNA extraction and reverse transcription-PCR
Primary cultures of SMCs were prepared from aortas of Wistar-
Kyoto rats [5], and maintained in DMEM supplemented with 10%
FCS containing 60 Wg/ml penicillin G; CHO cells were maintained in
similar medium. DNA [16] and DNA-free RNA [10] were extracted
from SMCs or aortic tissue and used, respectively, in PCR [16] utiliz-
ing primers that span the region 194^217 to 426^455 in the ALK-5
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cDNA (GenBank accession number L26110), or in reverse transcrip-
tion-PCR (RT-PCR) [10], utilizing primers that span the region 289^
317 to 407^435 in the ALK-5 cDNA. Ampli¢ed PCR and RT-PCR
fragments were electrophoresed through either 1% or 2.5% agarose/
ethidium bromide gels, gel puri¢ed, then cloned into pGEM and se-
quenced as previously described [10].
2.2. Construction of full length ‘long’ and ‘short’ ALK-5 cDNA
expression vectors
Full length rat ALK-5 cDNAs containing the entire coding region
either with (1506 bp) or without (1494 bp) the 12 nucleotides
GACCTTTTTCAG were constructed in the expression vector pCI-
neo (Promega) by a multistep procedure. Using a plasmid containing
nucleotide sequence upstream of the rat ALK-5 cDNA initiation co-
don [11], the 5P end of the cDNA was puri¢ed as a 285 bp fragment
(containing 40 nucleotides upstream of the initiation codon required
for appropriate expression of ALK-5 protein) after digestion with
EcoRI and Alw441. Internal fragments of either 714 bp (containing
the 12 nucleotides) or 702 bp (missing the 12 nucleotides) were gel
puri¢ed from Alw441 and KpnI digestion of RT-PCR products ob-
tained using primers spanning the regions 1^28 to 967^992 in the
ALK-5 cDNA. The 3P end of ALK-5 cDNA was prepared by ampli-
fying a fragment 576 bp in size using primers spanning 931^959 to
1477^1506 in the cDNA. After an intermediate cloning step, in which
a BstZI restriction site was placed at the 3P-terminus of this fragment,
it was digested with KpnI and BstZI, and gel puri¢ed as a 600 bp
fragment containing the ALK-5 termination codon TAA (nucleotides
1504^1506 in the cDNA). In two separate reaction tubes the 5P (285
bp), internal (714 or 702 bp), and 3P (600 bp) fragments were then
ligated into pCI-neo that had been digested with EcoRI and NotI, to
yield the respective full length ‘long’ (ALK-5L) and ‘short’ (ALK-5S)
ALK-5 isoform expression vectors. The integrity of each construct
was con¢rmed by sequencing of their entire coding region, and Qiagen
midi-prep systems were then used to prepare plasmid DNA for tran-
sient and stable transfections.
2.3. Transient and stable expression of ALK-5 isoform cDNA
Transient transfection of the two ALK-5 cDNAs into CHO cells
was carried out using lipofectamine essentially as described by the
manufacturer (Gibco BRL). Cell lysates were prepared 48 h later by
solubilization in lysis bu¡er (0.05% Triton X-100, 120 mmol/l Tris^
HCl, pH 8.7, 10 Wg/ml aprotinin, 10 Wg/ml leupeptin) and clearing by
centrifugation at 10 000Ug for 20 min. Western blot analysis of pro-
tein extracts (50 Wg) in 7.5% polyacrylamide gels with an ALK-5
antibody (SantaCruz Biotechnology, #sc-398) and the appropriate
horseradish peroxidase-linked secondary antibody (Amersham, ECL
kit) was carried out essentially as described by us previously [17]. For
stable expression into ALK-5-de¢cient mink lung epithelial cells (R1-
B/L17 cells, [18]) transfected cell clones were established after expo-
sure to 10% FCS supplemented with 1 mg/ml geneticin (G-418) for
12^14 days, expanded and screened for restoration of TGF-L re-
sponses.
2.4. [3H]thymidine incorporation assay, and Northern blot analysis of
plasminogen activator inhibitor-1 (PAI-1) mRNA levels
The e¡ect of TGF-L1 on DNA synthesis in R1-B cells stably trans-
fected with either ALK-5 cDNA was determined by measuring the
extent to which the cytokine inhibited [3H]thymidine incorporation
stimulated by 10% FCS. Brie£y, cells were cultured in 10% FCS-1
mg/ml G-418 until they reached semi-con£uence (cell densities V1^
2U105 cells/cm2), serum deprived for 48 h, then triplicate wells were
exposed to 10% FCS either alone or with the addition of varying
concentrations of TGF-L1. After 24 h exposure, the cells were washed
with DMEM, incubated for 2 h with [3H]thymidine, and then the
amount of radioactivity incorporated into their DNA was determined
as we have previously described [5]. For analysis of the e¡ects of
TGF-L1 on PAI-1 mRNA levels, total RNA was extracted from sta-
bly transfected quiescent cells (60 mm dishes) after exposure to 1 ng/
ml of the cytokine for 30 min, 1 h, 2 h, 4 h and 24 h, and then 15 Wg
was electrophoresed in 1% agarose/(2.2 mol/l) formaldehyde gels.
Northern blot detection of PAI-1 mRNA was carried out essentially
as previously described by us [5], using a [32P]dCTP-labelled (1 to
1.5U106 cpm/ml) PAI-1 cDNA fragment (389 base pairs) ampli¢ed
from mink lung epithelial cell RNA using primers that span the region
667^696 to 1026^1055 in the cDNA [19]. Autoradiographs were ana-
lyzed by laser densitometry at 600 nm, and the intensity of ribosomal
28S and 18S bands visualized under UV light was used to monitor
equal loading, and transfer, of RNA.
3. Results
3.1. Two ALK-5 isoforms are simultaneously co-expressed in
SMCs and arise from alternate usage of AG splice
acceptors at an intron-exon junction
Whilst we have previously shown the existence of an ALK-
5 isoform in SMCs that di¡ers from the initially characterized
ALK-5 cDNA in that it harbors an in-frame deletion of 12
nucleotides (GACCTTTTTCAG, nucleotides 326^337 in the
cDNA) adjacent to its transmembrane domain, the precise
molecular basis for the existence of these two ALK-5 forms
is not known. In addition, because SMCs exist in two pheno-
types, contractile in normal arteries and synthetic in culture,
we also elucidated the extent to which the two ALK-5 iso-
forms were co-expressed within these SMC phenotypes. RT-
PCR utilizing primers that £ank the region (nucleotides 289^
435 in the cDNA) in which the 12 nucleotides are present or
absent demonstrated the simultaneous co-expression of two
ALK-5 cDNA fragments (‘long’ ALK-5, ALK-5L ; ‘short’
ALK-5, ALK-5S) in both intact aortic tissue (contractile phe-
notype) and in cultured, serum-stimulated aortic SMCs (syn-
thetic phenotype) (Fig. 1); nucleotide sequencing (data not
shown) con¢rmed that the larger of these fragments was 147
bp in size, and was identical in sequence to the smaller 135 bp
fragment except that it contained the 12 nucleotides
GACCTTTTTCAG. These analyses indicated that of the
two isoforms, ALK-5S was a more abundant cDNA species
in both synthetic and contractile SMC phenotypes than was
ALK-5L.
To elucidate the molecular basis for the occurrence of these
two ALK-5 isoforms we used primers to amplify the region in
the ALK-5 gene that encompasses the 12 nucleotides present
or absent in either ALK-5L cDNA or ALK-5S cDNA, in
which based on the homologous region in the human ALK-
5 gene an intron is located [20]. By comparison to the human
exon/intron structure we utilized a sense primer that would
theoretically be present within exon 2 of the rat ALK-5 gene
(bases 194^217 of the cDNA), and an antisense primer that
would theoretically be present within exon 3 (bases 426^455 of
the cDNA). Using rat genomic DNA we ampli¢ed an V2.5
kb fragment with these primers, indicating the presence of a
Fig. 1. Agarose gel depicting the simultaneous co-expression of long
(147 bp fragment, ALK-5L) and short (135 bp fragment, ALK-5S)
ALK-5 cDNA isoforms in contractile aortic tissue (C) and synthetic
cultured SMCs (S). PX represents PX174 DNA digested with HaeIII
as molecular weight markers.
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large intron in this region. This was con¢rmed by nucleotide
sequencing analysis, with the intron being in the identical
position to that within the homologous region of the human
ALK-5 gene. The sequence of the intron 2/exon 3 junction
was characterized by the presence of two AG splice acceptor
motifs separated by 12 nucleotides (Fig. 2); alternate usage of
the leftward AG motif would give rise to the ALK-5L isoform
(1506 bp as a full length cDNA) whereas usage of the right-
ward AG motif would give rise to the ALK-5S isoform (1494
bp as a full length cDNA) (Fig. 2).
3.2. Cellular processing of alternate ALK-5 isoforms
In a previous study it has been demonstrated that a splice
variant of the type II receptor for the TGF-L superfamily
member anti-mullerian hormone (AMH), which contains a
four amino acid insertion in its extracellular domain, is inap-
propriately processed within the cell, thereby implicating it in
altered AMH responses [21]. Therefore, to begin to elucidate
the potential functional signi¢cance of SMC alternate ALK-5
isoform expression involving the presence or absence of the
four amino acids Gly-Pro-Phe-Ser in the extracellular domain,
we initially characterized the intracellular processing of the
two ALK-5 isoforms. In transient transfection experiments
into CHO cells using full length expression vectors containing
either the ALK-5L or ALK-5S cDNAs, immunoblotting with
an ALK-5 antibody demonstrated that in both cases a full
length ALK-5 protein was expressed (Fig. 3). Thus, unlike
the AMH receptor, it appears that the presence or absence
of the four amino acid Gly-Pro-Phe-Ser motif in ALK-5L or
ALK-5S, respectively, has no e¡ect on their intracellular pro-
cessing, suggesting that both isoforms have the potential to be
involved in transducing TGF-L responses.
3.3. Ability of alternate ALK-5 isoforms to transduce TGF-L
growth inhibitory and gene transcription responses
An ideal cellular model exists in which the functional sig-
ni¢cance of expression of the alternate ALK-5 isoforms at the
cell surface can be ascertained, which involves their stable
expression in Mv1Lu mink lung epithelial cells de¢cient for
ALK-5 function (R1-B/L17 cells) ; because of this ALK-5 de-
¢ciency these R1-B/L17 cells, unlike their parental Mv1Lu cell
line, are not growth inhibited by TGF-L and do not display
speci¢c gene transcription responses to the cytokine [22,23];
restoration of these responses can only occur in the setting of
Fig. 2. Nucleotide sequence of exon (nucleotides in upper case)-intron (nucleotides in lower case) junctions, indicating the origin of the long
(ALK-5L) and short (ALK-5S) ALK-5 cDNA isoforms arising from alternative splicing at AG splice acceptor motifs, designated by single- and
double-down arrows, respectively. The location of the alternate splicing in relation to the mature ALK-5 protein is shown (EC, extracellular;
TM, transmembrane; KI, kinase). The junctions between exon 2/intron 2/exon 3 are based on sequence homology to the human ALK-5 gene
[20]. Amino acid residues for each ALK-5 isoform are shown below nucleotides, with the deleted Gly-Pro-Phe-Ser motif in ALK-5S underlined.
Fig. 3. Expression of ALK-5L and ALK-5S cDNAs in CHO cells,
demonstrating that the intracellular processing of these alternate iso-
forms is identical. 1 Wg of either empty pCI-neo vector (‘Vector’) or
pCI-neo containing each of the respective ALK-5 cDNAs (‘ALK-
5L’, ‘ALK-5S’) were transiently transfected into CHO cells, then
samples of total lysates extracted 48 h later were resolved on 7.5%
SDS^polyacrylamide gels (‘Control’ denotes untransfected CHO
cells). Immunobinding was performed using an ALK-5-speci¢c pri-
mary antibody. The transiently expressed ALK-5 forms are indi-
cated by the bracket as V55 kDa proteins.
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exogenously restored ALK-5 function. Thus, we generated
R1-B cells stably expressing either ALK-5L or ALK-5S, and
determined the extent to which growth inhibitory and gene
transcription occurred after TGF-L exposure. In such stably
transfected cells cultured in 10% FCS, and exposed to varying
concentrations of TGF-L1 for 24 h, signi¢cant inhibition of
FCS-stimulated [3H]thymidine incorporation occurred with
TGF-L1 concentrations higher than 0.3 ng/ml (Fig. 4A). In-
terestingly, the ALK-5L isoform exhibited a slightly higher
potency in eliciting this inhibition than did the ALK-5S iso-
form (EC50 values of 0.34 ng/ml TGF-L1 and 0.41 ng/ml
TGF-L1, respectively).
There is some evidence to suggest that speci¢c structural
alterations within either ALK-5 or the type II TGF-L receptor
(TLR-II) are able to independently a¡ect cellular proliferation
and gene expression [24,25]. Therefore, we next determined
the capacity of the ALK-5L and ALK-5S isoforms to trans-
duce speci¢c gene transcription responses, by exposing stably
transfected cells to TGF-L1 over a 24 h time period and as-
saying for increases in mRNA levels for plasminogen activa-
tor inhibitor 1 (PAI-1). Although both ALK-5 isoforms were
able to increase PAI-1 mRNA levels in response to TGF-L1,
the extent of induction was greater with ALK-5S, reaching a
peak of 7-fold induction over basal levels at 1 h after cytokine
addition, as compared to the 3-fold induction for the same
exposure time with ALK-5L (Fig. 4B); after 4 h exposure to
TGF-L1, PAI-1 mRNA levels had returned to basal in both
the ALK-5L and ALK-5S transfected cells.
4. Discussion
In most cell types the broad diversity of responses elicited
by TGF-L has been shown to occur via signaling through a
receptor complex in which ALK-5, as the major type I recep-
tor for this ligand, is activated through transphosphorylation
by the type II receptor, TLR-II. In SMCs, TGF-L can invoke
a number of opposing e¡ects, either stimulating or inhibiting
cellular proliferation [5] and/or gene expression [26]. However,
the basis for these di¡erential e¡ects has remained largely
unknown. Clearly, one mechanism that could generate such
diversity in TGF-L responses involves alternative splicing in
the ALK-5 gene giving rise to multiple functional isoforms
with di¡erential signaling capacities. The data we have ob-
tained in the current study suggest that such a mechanism
occurs in SMCs. Nucleotide sequencing of the ALK-5 gene
encompassing the region in which the long (ALK-5L) and
short (ALK-5S) ALK-5 isoforms di¡er in structure due to
the absence or presence of 12 nucleotides encoding the Gly-
Pro-Phe-Ser motif adjacent to the transmembrane domain in-
dicates the presence of a large intron and the occurrence of
AG splice acceptor motifs located 12 nucleotides apart at an
intron/exon junction. The ALK-5L isoform in SMCs corre-
sponds to the ALK-5 isoform initially cloned from a rat brain
cDNA library [11], and originally postulated to be the ‘nor-
mally’ spliced receptor. The ALK-5S isoform exhibits greater
homology to the human ALK-5 cDNA [20], which has a
similar motif of 12 nucleotides missing in the corresponding
region. Whilst it remains uncertain as to which of the two
ALK-5 isoforms is the ‘normally’ spliced or the ‘alternatively’
spliced form of this TGF-L type I receptor in rat SMCs, their
high simultaneous co-expression in SMCs, either in the con-
tractile or synthetic phenotype, suggests that they ful¢l non-
redundant physiological roles, perhaps in regulating the TGF-
L response. Support for this possibility is provided from our
observations that the ALK-5L and ALK-5S isoforms were
not strictly equipotent in their capacity to transduce speci¢c
TGF-L responses, with ALK-5L displaying a lower EC50 val-
ue for TGF-L1 inhibition of [3H]thymidine incorporation into
cellular DNA, and ALK-5S displaying a greater ability to
induce PAI-1 mRNA levels in response to TGF-L1.
While the precise basis for the apparently di¡erential signal-
ing capacity of the ALK-5L and ALK-5S isoforms remains to
be fully elucidated, it may involve a mechanism in which the
alternate forms exhibit di¡erential conformations within the
TLR-II:TGF-L :ALK-5 signaling complex, arising through the
presence (ALK-5L) or absence (ALK-5S) of the proline resi-
due in the Gly-Pro-Phe-Ser motif located 11 amino acid res-
idues upstream of the transmembrane-spanning domain, re-
spectively, in each of these isoforms. Theoretically, the
absence or presence of the proline residue contained in this
four amino acid motif might thereby alter the interaction be-
tween the particular ALK-5 isoform and TLR-II in the het-
eromeric signaling complex. This possibility is further sug-
gested from recent ¢ndings demonstrating that the
transmembrane domains of ALK-5 and TLR-II play pivotal
roles in receptor association and activation, most likely by
in£uencing the relative orientation of each receptor within
Fig. 4. A: Restoration of TGF-L1 growth inhibitory responses in
ALK-5-de¢cient R1-B/L17 cells after stable transfection with ALK-
5L or ALK-5S isoform cDNA. Quiescent cells were exposed to 10%
FCS either alone or with the indicated concentrations of TGF-L1
for 24 h, and the growth inhibitory e¡ects were ascertained by as-
saying for reductions in FCS-stimulated [3H]thymidine incorporation
(cpm) in triplicate wells. Results represent the mean þ S.E.M. of
three independent experiments; C represents quiescent cells not ex-
posed to either 10% FCS or TGF-L1. B: Comparison of PAI-1
mRNA induction pro¢le stimulated by TGF-L1 in ALK-5-de¢cient
(R1-B/L17) cells stably transfected with either the ALK-5L or
ALK-5S isoform cDNA. Quiescent cell cultures were treated with
1 ng/ml of TGF-L1 for the indicated times in h (C represents no
TGF-L1 addition), then total RNA was isolated. Northern blot
analysis was performed using a [32P]dCTP-labelled PAI-1 cDNA
fragment.
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the signaling complex activated by TGF-L [27]. In this scenar-
io, both long-term inhibitory cellular proliferation responses
and shorter-term gene transcription responses would be trans-
duced by both ALK-5 isoforms, but in a quantitatively di¡er-
ential manner. In this regard, our data are consistent with
those of Pasche et al. [28], who identi¢ed in human tissue a
slightly shorter ALK-5 variant arising from the deletion of
three GCG motifs occurring in the NH2-terminus of the re-
ceptor, and resulting in the in-frame absence of three alanine
residues from the normal cluster of nine alanine residues.
These workers found that transfection of the shorter variant
ALK-5 cDNA into ALK-5-de¢cient cells (the same R1-B/L17
cell line utilized in our study) resulted in the restoration of
both TGF-L growth inhibitory and gene transcription re-
sponses; however, a tendency was seen for the shorter variant
ALK-5 to be more potent in some cases at restoring these
TGF-L responses than the corresponding normally processed
ALK-5.
In conclusion, our study demonstrates that SMCs are capa-
ble of generating alternate functional ALK-5 isoforms that
appear, however, not strictly equipotent in their capacity to
transduce growth inhibitory or gene transcription responses
for TGF-L1. The relatively high simultaneous co-expression
of these isoforms in either contractile or synthetic SMCs sug-
gests that their expression may be involved in regulating the
response of such cells to the presence of TGF-L.
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